<DOC>
	<DOCNO>NCT00473577</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) CRA-024781 IV give 2-hour intravenous infusion patient refractory solid hematologic malignancy . To evaluate safety tolerability , pharmacokinetics pharmacodynamics , evaluate bioavailability CRA-024781 IV administer single oral dose .</brief_summary>
	<brief_title>Study Tolerability , Safety , Pharmacokinetics CRA-024781 Cancer Patients</brief_title>
	<detailed_description>Patients receive single oral dose CRA-024781 one week begin intravenous dose . Blood sample pharmacokinetic pharmacodynamic analysis collect several occasion prior start intravenous treatment . The intravenous treatment consist 3 consecutive day CRA-024781 IV administer 2-hour IV infusion every 3 week 4 week cycle . Assessment extent disease perform every 8 week .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Abexinostat</mesh_term>
	<criteria>age ≥ 18 year histologically confirm solid hematologic malignancy refractory standard therapy standard therapy exist estimate life expectancy &gt; 12 week ECOG performance grade ≤ 2 creatinine ≤ 1.5 X institutional upper limit normal creatinine clearance &gt; 50 mL/min total bilirubin within institutional limit ( unless elevate document Gilbert 's syndrome ) AST ALT ≤ 2.5 X institutional upper limit normal ( ≤ 5 x institutional upper limit normal presence liver metastasis ) platelet count ≥ 100,000/µL absolute neutrophil count ( ANC ) ≥ 1500/µL Hgb ≥ 9.0 g/dL patient previously treat brain metastasis corticosteroid eligible effective contraceptive method ( e.g. , intrauterine device , oral contraceptive , barrier device ) must use study male female patient childbearing potential ability understand willingness sign write informed consent patient immunotherapy , chemotherapy , radiotherapy within 4 week ( within 6 week nitrosoureas mitomycin C ) prior study entry ; study entry define first day drug dose patient undergone major surgery within 4 week prior study entry patient receive another investigational drug patient active CNS metastases leptomeningeal disease control prior surgery radiotherapy uncontrolled illness include limited : ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV heart failure ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement risk factor QTc prolongation and/or Torsade de Pointes patient know HIV infection concurrent systemic hormonal therapy except : stable LHRH agonist therapy prostate cancer ; hormonal therapy ( e.g. , megestrol ) appetite stimulation ; nasal , ophthalmic , topical glucocorticoid preparation appropriate ; stable oral glucocorticoid mineralocorticoid replacement adrenal insufficiency ; oral contraceptive patient medical psychiatric illness organ dysfunction , opinion Investigator , would either compromise patient 's safety interfere evaluation safety study agent pregnant lactate woman ( female patient must negative serum pregnancy test within 7 day study entry ) patient previously receive histone deacetylase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>